

Carlo Patrono

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5481163/carlo-patrono-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

299
papers

37,470⁰
citations

83
h-index

192
g-index

333
ext. papers

43,148⁸
ext. citations

9.6
avg, IF

7.39
L-index

#	Paper	IF	Citations
299	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2016, 37, 267-315	9.5	3850
298	Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. <i>Lancet, The</i> , 2009, 373, 1849-60	40	2427
297	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. <i>European Heart Journal</i> , 2020, 41, 407-477	9.5	1835
296	Platelet activation and atherothrombosis. <i>New England Journal of Medicine</i> , 2007, 357, 2482-94	59.2	1573
295	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , 2013, 34, 3035-87	9.5	1444
294	The coxibs, selective inhibitors of cyclooxygenase-2. <i>New England Journal of Medicine</i> , 2001, 345, 433-42	59.2	1214
293	Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. <i>Journal of the National Cancer Institute</i> , 2002, 94, 252-66	9.7	1182
292	Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. <i>BMJ, The</i> , 2006, 332, 1302-8	5.9	1000
291	Low-dose aspirin for the prevention of atherothrombosis. <i>New England Journal of Medicine</i> , 2005, 353, 2373-83	59.2	870
290	Fourth universal definition of myocardial infarction (2018).. <i>European Heart Journal</i> , 2019, 40, 237-269	9.5	851
289	Aspirin as an antiplatelet drug. <i>New England Journal of Medicine</i> , 1994, 330, 1287-94	59.2	774
288	Efficacy and safety of low-dose aspirin in polycythemia vera. <i>New England Journal of Medicine</i> , 2004, 350, 114-24	59.2	744
287	Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. <i>Journal of Clinical Investigation</i> , 1982, 69, 1366-72	15.9	723
286	In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. <i>Circulation</i> , 1999, 99, 224-9	16.7	646
285	Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. <i>Thrombosis Research</i> , 1980, 17, 317-27	8.2	573
284	Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. <i>Journal of Clinical Oncology</i> , 2005, 23, 2224-32	2.2	504
283	Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. <i>Chest</i> , 2004, 126, 234S-264S	5.3	494

282	Thromboxane biosynthesis and platelet function in type II diabetes mellitus. <i>New England Journal of Medicine</i> , 1990 , 322, 1769-74	59.2	487
281	Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. <i>Circulation</i> , 1983 , 67, 1174-7	16.7	420
280	Platelet activation in obese women: role of inflammation and oxidant stress. <i>JAMA - Journal of the American Medical Association</i> , 2002 , 288, 2008-14	27.4	406
279	Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997 , 17, 2309-15	9.4	404
278	Platelet-active drugs : the relationships among dose, effectiveness, and side effects. <i>Chest</i> , 2001 , 119, 39S-63S	5.3	380
277	Clinical pharmacology of platelet cyclooxygenase inhibition. <i>Circulation</i> , 1985 , 72, 1177-84	16.7	362
276	The role of aspirin in cancer prevention. <i>Nature Reviews Clinical Oncology</i> , 2012 , 9, 259-67	19.4	352
275	Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , 2008 , 133, 199S-233S	5.3	350
274	COVID-19 vaccines: where we stand and challenges ahead. <i>Cell Death and Differentiation</i> , 2021 , 28, 626-637	6.3	337
273	Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. <i>Blood</i> , 2005 , 105, 2664-70	2.2	332
272	In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997 , 17, 3230-5	9.4	320
271	Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin. <i>New England Journal of Medicine</i> , 1984 , 310, 279-83	59.2	312
270	Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. <i>Journal of Clinical Investigation</i> , 2001 , 108, 7-13	15.9	287
269	Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 7634-9	11.5	260
268	Lipid peroxidation in diabetes mellitus. <i>Antioxidants and Redox Signaling</i> , 2005 , 7, 256-68	8.4	248
267	Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. <i>European Heart Journal</i> , 2004 , 25, 166-81	9.5	245
266	Aspirin resistance: definition, mechanisms and clinical read-outs. <i>Journal of Thrombosis and Haemostasis</i> , 2003 , 1, 1710-3	15.4	224
265	The clinical significance of inhibition of renal prostaglandin synthesis. <i>Kidney International</i> , 1987 , 32, 1-12	9.9	215

264	Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995 , 15, 247-51	9.4	205
263	Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. <i>Circulation</i> , 2004 , 109, 1468-71	16.7	195
262	Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". <i>Journal of the American College of Cardiology</i> , 2009 , 53, 667-77	15.1	193
261	Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. <i>Circulation</i> , 2000 , 102, 1007-13	16.7	187
260	Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. <i>Circulation</i> , 2002 , 106, 2800-5	16.7	180
259	Estimated rate of thromboxane secretion into the circulation of normal humans. <i>Journal of Clinical Investigation</i> , 1986 , 77, 590-4	15.9	180
258	Evidence for a direct stimulatory effect of prostacyclin on renin release in man. <i>Journal of Clinical Investigation</i> , 1982 , 69, 231-9	15.9	176
257	The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 1220-30	15.4	171
256	Antiplatelet agents for the treatment and prevention of atherothrombosis. <i>European Heart Journal</i> , 2011 , 32, 2922-32	9.5	160
255	Increased thromboxane biosynthesis in type IIa hypercholesterolemia. <i>Circulation</i> , 1992 , 85, 1792-8	16.7	158
254	Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 1985 , 76, 1011-8	15.9	156
253	Aspirin and Cancer. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 967-76	15.1	153
252	Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. <i>Epidemiology</i> , 2000 , 11, 382-7	3.1	153
251	Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. <i>Blood</i> , 2012 , 119, 3595-603	2.2	151
250	Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. <i>Circulation</i> , 1997 , 96, 69-75	16.7	142
249	Platelet-active drugs: the relationships among dose, effectiveness, and side effects. <i>Chest</i> , 1998 , 114, 470S-488S	5.3	139
248	Leukotrienes in the rat central nervous system. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1984 , 81, 6212-6	11.5	138
247	ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary. <i>Diabetes and Vascular Disease Research</i> , 2014 , 11, 133-73	3.3	137

246	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2015 , 36, 3238-49	9.5	129
245	Cyclooxygenase inhibitors: From pharmacology to clinical read-outs. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2015 , 1851, 422-32	5	126
244	Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect. <i>Journal of Clinical Investigation</i> , 1983 , 71, 762-8	15.9	120
243	Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. <i>Circulation</i> , 2003 , 107, 3199-203	16.7	119
242	Cyclooxygenase-2 expression and inhibition in atherothrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004 , 24, 246-55	9.4	115
241	Mechanisms, Consequences, and Prevention of Coronary Graft Failure. <i>Circulation</i> , 2017 , 136, 1749-1764	16.7	113
240	Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. <i>Journal of Clinical Investigation</i> , 1993 , 92, 1400-6	15.9	108
239	Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. <i>Circulation</i> , 1997 , 96, 1109-16	16.7	107
238	Nutraceuticals in diabetes and metabolic syndrome. <i>Cardiovascular Therapeutics</i> , 2010 , 28, 216-26	3.3	106
237	Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. <i>Journal of Clinical Investigation</i> , 1999 , 103, 1469-77	15.9	106
236	The synovial prostaglandin system in chronic inflammatory arthritis: differential effects of steroidal and nonsteroidal anti-inflammatory drugs. <i>British Journal of Pharmacology</i> , 1981 , 73, 893-901	8.6	104
235	Oxidative stress and platelet activation in homozygous homocystinuria. <i>Circulation</i> , 2001 , 104, 1124-8	16.7	103
234	Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. <i>Trends in Pharmacological Sciences</i> , 1989 , 10, 453-8	13.2	103
233	Effects of intravenous prostacyclin in variant angina. <i>Circulation</i> , 1982 , 65, 470-7	16.7	103
232	Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. <i>Oncotarget</i> , 2016 , 7, 32462-77	3.3	101
231	Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1760-1776	15.1	100
230	Improvement of renal function with selective thromboxane antagonism in lupus nephritis. <i>New England Journal of Medicine</i> , 1989 , 320, 421-5	59.2	100
229	Release of leukotriene C4 from human polymorphonuclear leucocytes as determined by radioimmunoassay. <i>FEBS Letters</i> , 1982 , 146, 111-4	3.8	100

228	Insulin resistance as a determinant of platelet activation in obese women. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 2531-8	15.1	98
227	Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 231-241	18.8	96
226	Long-lived enzymatic metabolites of thromboxane B2 in the human circulation. <i>Analytical Biochemistry</i> , 1986 , 155, 198-205	3.1	96
225	Radioimmunoassay measurement of prostaglandins E2 and F2alpha in human urine. <i>Journal of Endocrinological Investigation</i> , 1979 , 2, 173-82	5.2	95
224	Drug insight: aspirin resistance--fact or fashion?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007 , 4, 42-50		94
223	Effects of vitamin E supplementation on F(2)-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. <i>Circulation</i> , 2000 , 102, 539-45	16.7	94
222	Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 391-7	15.1	91
221	Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 80, 264-74	6.1	89
220	Eicosanoids and Iso-Eicosanoids: Constitutive, Inducible and Transcellular Biosynthesis in Vascular Disease. <i>Thrombosis and Haemostasis</i> , 1998 , 79, 691-705	7	89
219	Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. <i>Arthritis and Rheumatism</i> , 2003 , 48, 12-20		86
218	Dissociation of Platelet Activation and Spontaneous Myocardial Ischemia in Unstable Angina. <i>Thrombosis and Haemostasis</i> , 1990 , 63, 163-168	7	85
217	The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. <i>Blood</i> , 2010 , 115, 1054-61	22.2	83
216	Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1989 , 992, 66-70	4	83
215	Nonsteroidal anti-inflammatory drugs and the heart. <i>Circulation</i> , 2014 , 129, 907-16	16.7	82
214	Increased thromboxane biosynthesis in patients with acute cerebral ischemia. <i>Stroke</i> , 1993 , 24, 219-23	6.7	80
213	In vivo lipid peroxidation and platelet activation in cystic fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000 , 162, 1195-201	10.2	77
212	Antiplatelet drugs. <i>British Journal of Pharmacology</i> , 2006 , 147 Suppl 1, S241-51	8.6	76
211	Determinants of F2-isoprostane biosynthesis and inhibition in man. <i>Chemistry and Physics of Lipids</i> , 2004 , 128, 149-63	3.7	76

210	Evidence for an extra-renal origin of urinary prostaglandin E2 in healthy men. <i>Prostaglandins</i> , 1979 , 18, 623-9		76
209	The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 74-85	15.1	75
208	Determinants of platelet activation in human essential hypertension. <i>Hypertension</i> , 2004 , 43, 64-70	8.5	73
207	Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects. <i>Chest</i> , 1995 , 108, 247S-257S	5.3	73
206	Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 957-64	3.8	73
205	Aspirin: promise and resistance in the new millennium. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008 , 28, s25-32	9.4	72
204	Coronary flow regulation in patients with ischemic heart disease: release of purines and prostacyclin and the effect of inhibitors of prostaglandin formation. <i>Circulation</i> , 1985 , 71, 1113-20	16.7	72
203	Increased Thromboxane Biosynthesis in Essential Thrombocythemia. <i>Thrombosis and Haemostasis</i> , 1995 , 74, 1225-1230	7	72
202	Pharmacologic modulation of the autonomic nervous system in the prevention of sudden cardiac death. A study with propranolol, methacholine and oxotremorine in conscious dogs with a healed myocardial infarction. <i>Journal of the American College of Cardiology</i> , 1993 , 22, 283-90	15.1	71
201	Evidence for episodic platelet activation in acute ischemic stroke. <i>Stroke</i> , 1994 , 25, 278-81	6.7	70
200	Determinants of the interindividual variability in response to antiplatelet drugs. <i>Journal of Thrombosis and Haemostasis</i> , 2005 , 3, 1597-602	15.4	68
199	Characterization of furosemide-induced activation of the renal prostaglandin system. <i>European Journal of Pharmacology</i> , 1979 , 60, 181-7	5.3	68
198	Role of prostaglandin F2 in human cerebral vasospasm. <i>Journal of Neurosurgery</i> , 1974 , 41, 293-9	3.2	68
197	Platelet activation and lipid peroxidation in patients with acute ischemic stroke. <i>Stroke</i> , 1997 , 28, 1557-63	6.7	67
196	Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulphonamide (NS-398) and 5-methanesulphonamido-6-(2,4-difluorothio-phenyl)-1-indanone (L-745,337), on the cyclo-oxygenase activity of human blood prostaglandin endoperoxide synthases. <i>British Journal of Pharmacology</i> , 1995 , 116, 2429-34	8.6	66
195	Effect of prostaglandin synthesis inhibitors on basal and carbon dioxide stimulated cerebral blood flow in man. <i>Acta Physiologica Scandinavica</i> , 1983 , 117, 203-11		65
194	Isoprostane formation and inhibition in atherothrombosis. <i>Current Opinion in Pharmacology</i> , 2005 , 5, 198-203	5.1	63
193	Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 828-37	15.4	62

192	Determinants of platelet activation in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2007 , 28, 336-42	5.6	62
191	Induction of prostaglandin endoperoxide synthase-2 in human monocytes associated with cyclo-oxygenase-dependent F2-isoprostane formation. <i>British Journal of Pharmacology</i> , 1996 , 118, 1285-93	8.6	62
190	Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. <i>Critical Reviews in Oncology/Hematology</i> , 1995 , 20, 203-22	7	62
189	Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. <i>Blood</i> , 2013 , 121, 1701-11	2.2	61
188	Nonsteroidal antiinflammatory drugs: past, present and future. <i>Pharmacological Research</i> , 2009 , 59, 285-92	6.2	60
187	Release of two vasodilators, adenosine and prostacyclin, from isolated rabbit hearts during controlled hypoxia. <i>Journal of Physiology</i> , 1983 , 340, 487-501	3.9	60
186	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <i>European Heart Journal</i> , 2018 , 39, 1672-1686f	9.5	59
185	Role of aspirin in primary prevention of cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2019 , 16, 675-685	1.8	57
184	Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action. <i>Journal of Thrombosis and Haemostasis</i> , 2014 , 12, 1320-30	15.4	57
183	Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. <i>Journal of Thrombosis and Haemostasis</i> , 2003 , 1, 250-6	15.4	55
182	Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?. <i>European Heart Journal</i> , 2013 , 34, 3403-11	9.5	54
181	Aspirin: new cardiovascular uses for an old drug. <i>American Journal of Medicine</i> , 2001 , 110, 62S-65S	2.4	52
180	Low-dose aspirin, coxibs, and other NSAIDs: a clinical mosaic emerges. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2009 , 9, 31-9		51
179	Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen?. <i>Stroke</i> , 1996 , 27, 756-60	6.7	50
178	Mechanisms of Bleeding and Thrombosis in Myeloproliferative Disorders. <i>Thrombosis and Haemostasis</i> , 1997 , 78, 617-621	7	49
177	Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis: A mechanistic and clinical perspective. <i>Vascular Pharmacology</i> , 2016 , 78, 1-9	5.9	47
176	Increased platelet activation in the chronic phase after cerebral ischemia and intracerebral hemorrhage. <i>Stroke</i> , 1999 , 30, 546-9	6.7	46
175	Platelet activating factor (PAF) as a mediator of injury in nephrotoxic nephritis. <i>Kidney International</i> , 1987 , 31, 1248-56	9.9	43

174	Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011 , 336, 391-402	4.7	41
173	Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 63, 672-81	6.1	40
172	Proarrhythmic activity of intracoronary endothelin in dogs: relation to the site of administration and to changes in regional flow. <i>Journal of Cardiovascular Pharmacology</i> , 1991 , 17, 1007-14	3.1	39
171	Platelet activation and inhibition in unstable coronary syndromes. <i>American Journal of Cardiology</i> , 1997 , 80, 17E-20E	3	38
170	Eicosanoid biosynthesis and action: novel opportunities for pharmacological intervention. <i>FASEB Journal</i> , 1989 , 3, 1941-8	0.9	38
169	Physiologic variables affecting thromboxane B2 production in human whole blood. <i>Thrombosis Research</i> , 1985 , 37, 1-8	8.2	38
168	Aspirin, platelet inhibition and cancer prevention. <i>Platelets</i> , 2018 , 29, 779-785	3.6	37
167	Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function. <i>European Heart Journal</i> , 1985 , 6, 409-17	9.5	36
166	Renal effects of nonsteroidal anti-inflammatory drugs in chronic glomerular disease. <i>American Journal of Medicine</i> , 1986 , 81, 71-83	2.4	34
165	In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes. <i>Diabetes</i> , 2016 , 65, 503-9	0.9	33
164	A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. <i>Blood</i> , 2020 , 136, 171-182	2.2	33
163	Off-Pump Coronary Artery Bypass Grafting: 30 Years of Debate. <i>Journal of the American Heart Association</i> , 2018 , 7, e009934	6	33
162	In vivo platelet activation in diabetes mellitus. <i>Seminars in Thrombosis and Hemostasis</i> , 1991 , 17, 422-5	5.3	32
161	Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 238-245	6.1	31
160	Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs. <i>Current Cardiology Reports</i> , 2016 , 18, 25	4.2	31
159	Effects of nabumetone on prostanoid biosynthesis in humans. <i>Clinical Pharmacology and Therapeutics</i> , 1995 , 58, 335-41	6.1	31
158	Cigarette smoking knowledge and perceptions among students in four Italian medical schools. <i>Nicotine and Tobacco Research</i> , 2012 , 14, 1065-72	4.9	29
157	Increased thromboxane biosynthesis is associated with poststroke dementia. <i>Stroke</i> , 1999 , 30, 1542-7	6.7	29

156	Effects of sulindac on renal and extrarenal eicosanoid synthesis. <i>Clinical Pharmacology and Therapeutics</i> , 1987 , 41, 380-3	6.1	29
155	Arterial Grafts for Coronary Bypass: A Critical Review After the Publication of ART and RADIAL. <i>Circulation</i> , 2019 , 140, 1273-1284	16.7	28
154	Cyclooxygenase-2 polymorphism: putting a brake on the inflammatory response to vascular injury?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002 , 22, 1516-8	9.4	28
153	Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage?. <i>Thrombosis Research</i> , 1998 , 92, S7-12	8.2	27
152	Enzyme immunometric assay for endothelin using tandem monoclonal antibodies. <i>Journal of Immunological Methods</i> , 1993 , 162, 179-92	2.5	27
151	Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction. <i>American Journal of Cardiology</i> , 1985 , 55, 589-90	3	27
150	Pulmonary formation of prostacyclin in man. <i>Prostaglandins</i> , 1981 , 22, 323-32		27
149	Effects of racemic, S- and R-indobufen on cyclooxygenase and lipoxygenase activities in human whole blood. <i>European Journal of Pharmacology</i> , 1990 , 191, 83-8	5.3	26
148	The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 70, 475-83	6.1	26
147	Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 854-862	18.8	25
146	Helicobacter pylori infection causes persistent platelet activation in vivo through enhanced lipid peroxidation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005 , 25, 246-51	9.4	25
145	Thromboxane biosynthesis and metabolism in relation to cardiovascular risk factors. <i>Trends in Cardiovascular Medicine</i> , 1992 , 2, 15-20	6.9	25
144	Measurement of Thromboxane Biosynthesis in Health and Disease. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1244	5.6	23
143	Aspirin, but not heparin, suppresses the transient increase in thromboxane biosynthesis associated with cardiac catheterization or coronary angioplasty. <i>Journal of the American College of Cardiology</i> , 1993 , 21, 1377-81	15.1	23
142	Hemodynamic and tubular effects of endothelin and thromboxane in the isolated perfused rat kidney. <i>European Journal of Pharmacology</i> , 1989 , 171, 127-34	5.3	23
141	Aspirin for the prevention of coronary thrombosis: current facts and perspectives. <i>European Heart Journal</i> , 1986 , 7, 454-9	9.5	23
140	Low-Dose Aspirin Acetylates Cyclooxygenase-1 in Human Colorectal Mucosa: Implications for the Chemoprevention of Colorectal Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 52-61	6.1	22
139	Long-term thromboxane-synthase inhibition prolongs survival in murine lupus nephritis. <i>Kidney International</i> , 1995 , 47, 1168-75	9.9	22

138	The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. <i>Blood Cancer Journal</i> , 2018 , 8, 49	7	21
137	Release of prostaglandin F1alpha and F2alpha from superfused platelets: quantitative evaluation of the inhibitory effects of some aspirin-like drugs. <i>Prostaglandins</i> , 1975 , 9, 557-68		21
136	Effects of Unfractionated and Low Molecular Weight Heparins on Platelet Thromboxane Biosynthesis <i>In Vivo</i> <i>Thrombosis and Haemostasis</i> , 1994 , 72, 942-946	7	21
135	Should the 1h algorithm for rule in and rule out of acute myocardial infarction be used universally?. <i>European Heart Journal</i> , 2016 , 37, 3316-3323	9.5	21
134	Guía ESC 2015 sobre el tratamiento de los síndromes coronarios agudos en pacientes sin elevación persistente del segmento ST: Grupo de Trabajo de la Sociedad Europea de Cardiología (ESC) para el tratamiento de los síndromes coronarios agudos en pacientes sin elevación persistente del segmento ST. <i>Revista Espanola De Cardiologia</i> , 2015 , 68, 1125.e1-1125.e64	1.5	20
133	The PGH-synthase system and isozyme-selective inhibition. <i>Journal of Cardiovascular Pharmacology</i> , 2006 , 47 Suppl 1, S1-6	3.1	20
132	Role of enhanced glomerular synthesis of thromboxane A2 in progressive kidney disease. <i>Kidney International</i> , 1990 , 38, 447-58	9.9	20
131	Aspirin and Other COX-1 inhibitors. <i>Handbook of Experimental Pharmacology</i> , 2012 , 137-64	3.2	19
130	Regulation of endothelin-1 biosynthesis. <i>Annals of the New York Academy of Sciences</i> , 1994 , 714, 109-21	6.5	19
129	Aspirin intolerance: unaltered susceptibility of platelet cyclo-oxygenase to inhibition by aspirin in vitro. <i>Journal of Allergy and Clinical Immunology</i> , 1978 , 62, 271-5	11.5	19
128	On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 849-858	6.1	18
127	The future of antiplatelet therapy in cardiovascular disease. <i>Annual Review of Medicine</i> , 2010 , 61, 49-61	17.4	18
126	Behavior of pancreatic glucagon, insulin, and HGH in liver cirrhosis, after arginine and I.V. glucose. <i>Acta Diabetologica Latina</i> , 1974 , 11, 330-9		18
125	Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinaemia due to MTHFR 677 C-T polymorphism. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 533-42	7	17
124	Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , 1993 , 13, 1346-9		17
123	Prostacyclin does not affect insulin secretion in humans. <i>Prostaglandins</i> , 1981 , 21, 379-85		16
122	In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 118-27	7	15
121	Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 914-22	15.4	15

120	Antiplatelet agents in the prevention of diabetic vascular complications. <i>Diabetes/metabolism Reviews</i> , 1993 , 9, 177-88		15
119	Fractional conversion of thromboxane A2 and B2 to urinary 2,3-dinor-thromboxane B2 and 11-dehydrothromboxane B2 in the cynomolgus monkey. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1989 , 992, 71-7	4	15
118	In Silico Modeling of the Antiplatelet Pharmacodynamics of Low-dose Aspirin in Health and Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 823-831	6.1	14
117	Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies. <i>Seminars in Thrombosis and Hemostasis</i> , 2006 , 32, 251-9	5.3	14
116	Release of contracting autacoids by aortae of normal and atherosclerotic rabbits. <i>Journal of Cardiovascular Pharmacology</i> , 1992 , 20 Suppl 12, S208-10	3.1	14
115	Leukotriene C4 stimulates LH secretion from rat pituitary cells in vitro. <i>European Journal of Pharmacology</i> , 1984 , 106, 459-60	5.3	14
114	The involvement of arachidonic acid metabolism in the control of renin release. <i>Journal of Endocrinological Investigation</i> , 1980 , 3, 193-201	5.2	14
113	Cardiac formation of prostacyclin during cardioplegia in man. <i>Prostaglandins</i> , 1982 , 24, 5-19		14
112	Echinococcus granulosus: evaluation of purified antigens immunoreactivity. <i>Experimental Parasitology</i> , 1974 , 35, 52-60	2.1	14
111	In vivo expression of mutant preproendothelins: hierarchy of processing events but no strict requirement of Trp-Val at the processing site. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993 , 90, 3923-7	11.5	13
110	Plasma and synovial fluid pharmacokinetics and prostaglandin inhibitory effect of indoprofen in patients with rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 1980 , 9, 123-6	1.9	13
109	Prostacyclin stimulates the adenylate cyclase system of human thyroid tissue. <i>Prostaglandins</i> , 1981 , 22, 105-15		12
108	Effect of Low-dose and Standard-dose Aspirin on PGE Biosynthesis Among Individuals with Colorectal Adenomas: A Randomized Clinical Trial. <i>Cancer Prevention Research</i> , 2020 , 13, 877-888	3.2	12
107	Differential effects of leukotriene C4 on endothelin-1 and prostacyclin release by cultured vascular cells. <i>Pharmacological Research</i> , 1993 , 27, 281-5	10.2	11
106	Thromboxane synthesis inhibitors and receptor antagonists. <i>Thrombosis Research</i> , 1990 , 11, 15-23	8.2	11
105	Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 891-896	7	11
104	Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives. <i>Leukemia and Lymphoma</i> , 1996 , 22 Suppl 1, 83-6	1.9	10
103	Modulation of the expression and activity of cyclooxygenases in normal and accelerated erythropoiesis. <i>Experimental Hematology</i> , 2004 , 32, 925-34	3.1	10

102	Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective. <i>Diabetes Research and Clinical Practice</i> , 2020 , 160, 108008	7.4	10
101	Platelet-Specific Deletion of Cyclooxygenase-1 Ameliorates Dextran Sulfate Sodium-Induced Colitis in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019 , 370, 416-426	4.7	9
100	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2014 , 35, 1824-1824	9.5	9
99	Selective COX-2 inhibitors: where do we go from here?. <i>Lancet, The</i> , 2008 , 372, 1712-3	4.0	9
98	Evidence for a direct vasoconstrictor effect of big endothelin-1 in the rat kidney. <i>European Journal of Pharmacology</i> , 1992 , 221, 267-73	5.3	9
97	COVID 19: in the eye of the cytokine storm. <i>European Heart Journal</i> , 2021 , 42, 150-151	9.5	9
96	The key contribution of platelet and vascular arachidonic acid metabolism to the pathophysiology of atherothrombosis. <i>Cardiovascular Research</i> , 2021 , 117, 2001-2015	9.9	9
95	Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. <i>Revista Espanola De Cardiologia</i> , 2014 , 67, 136.e1-136.e56	1.5	8
94	Questions and answers on coronary revascularization: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016 , 37, e8-e14	9.5	7
93	Questions and answers on diagnosis and risk assessment: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016 , 37, e15-e21	9.5	7
92	Knowledge about health effects of cigarette smoking and quitting among Italian university students: the importance of teaching nicotine dependence and treatment in the medical curriculum. <i>BioMed Research International</i> , 2014 , 2014, 321657	3	7
91	Heterologous in vivo processing of human preproendothelin 1 into bioactive peptides. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991 , 88, 8939-43	11.5	7
90	Conflicting results on the efficacy of remdesivir in hospitalized Covid-19 patients: comment on the Adaptive Covid-19 Treatment Trial. <i>European Heart Journal</i> , 2020 , 41, 4387-4388	9.5	6
89	Coxibs and traditional NSAIDs for pain relief - Authors' reply. <i>Lancet, The</i> , 2014 , 383, 122	4.0	6
88	Role of clinical pharmacology in the development of antiplatelet drugs. <i>Clinical Therapeutics</i> , 2014 , 36, 2096-2111	3.5	6
87	Growth abnormalities in cultured mesangial cells from rats with spontaneous glomerulosclerosis. <i>Kidney International</i> , 1995 , 47, 106-13	9.9	6
86	In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance. <i>Diabetes/Metabolism Research and Reviews</i> , 2020 , 36, e3232	7.5	6
85	CardioPulse: What's new in the 2015 European Society of Cardiology Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016 , 37, 206-7	9.5	5

84	Pharmacologic modulation of arachidonic acid metabolism in man. A minireview with emphasis on radioimmunological methods used to quantitate drug effects. <i>International Journal of Immunopharmacology</i> , 1982 , 4, 127-33		5
83	Letter: Do pituitary prostaglandins play an essential role in the action of LH-RH in man?. <i>Prostaglandins</i> , 1974 , 6, 345-8		5
82	Do VERTIS-CV trial results question a class-effect of cardiovascular protection with sodium-glucose cotransporter 2 inhibitors?. <i>European Heart Journal</i> , 2020 , 41, 4232-4233	9.5	4
81	Long-term maintenance of thromboxane inhibition by two different aspirin regimens in patients with unstable angina. <i>Thrombosis Research</i> , 1990 , 60, 169-75	8.2	4
80	Inhibition of renal prostaglandin synthesis in man: methodological and clinical implications. <i>Scandinavian Journal of Rheumatology</i> , 1986 , 62, 14-25	1.9	4
79	Clinical Perspectives and Pearls from the 2015 ESC NSTEMI-ACS Guidelines. <i>Current Cardiology Reports</i> , 2016 , 18, 48	4.2	4
78	Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context. <i>Cardiovascular Research</i> , 2017 , 113, e61-e63	9.9	3
77	Radioimmunoassay of 11-dehydrothromboxane B ₂ . <i>Methods in Enzymology</i> , 1990 , 187, 34-42	1.7	3
76	Tissue-selective inhibition of prostaglandin and thromboxane synthesis in man: investigative and therapeutic implications. <i>Clinical Physiology</i> , 1984 , 4, 443-7		3
75	Characterization of Biochemical and Functional Effects of Antiplatelet Drugs as a Key to Their Clinical Development. <i>Thrombosis and Haemostasis</i> , 1995 , 74, 396-400	7	3
74	The REDUCE-IT verdict on eicosapentaenoic acid and cardiovascular outcome challenged with STRENGTH. <i>European Heart Journal</i> , 2021 , 42, 370-371	9.5	3
73	Thromboxane biosynthesis and metabolism in relation to cardiovascular risk factors. <i>Agents and Actions Supplements</i> , 1992 , 37, 10-7	0.2	3
72	Nonsteroidal antiinflammatory drugs 2015 , 415-422		3
71	The widely promoted antimalarial drug hydroxychloroquine confers no mortality benefit in hospitalized patients with COVID-19: comment on the 'Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19'. <i>European Heart Journal</i> , 2020 , 41, 4389-4390	9.5	3
70	Early rhythm control for early atrial fibrillation? Comment on the EAST-AFNET 4 Trial. <i>European Heart Journal</i> , 2020 , 41, 3987-3988	9.5	3
69	The key role of blood pressure lowering in cardiovascular prevention irrespective of baseline blood pressure and risk profile. <i>European Heart Journal</i> , 2021 , 42, 2814-2815	9.5	3
68	The EMPEROR-Preserved study: end of the search for the "Phoenix" or beginning of a new season for trials in heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2021 , 42, 4621-4623	9.5	3
67	Questions and answers on antithrombotic therapy: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016 , 37, e1-e7	9.5	2

66	El ácido acetilsalicílico continúa siendo objeto de investigación y debate 115 años después de su síntesis. <i>Revista Española De Cardiología</i> , 2013 , 66, 251-254	1.5	2
65	Unstable coronary artery disease: need for long-term antithrombotic treatment? Aspirin alone may not be the ideal antithrombotic strategy, but that's what we have adequate trial data for. <i>Cardiovascular Research</i> , 1997 , 33, 295-6	9.9	2
64	Guest authorship, mortality reporting, and integrity in rofecoxib studies. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 300, 901; author reply 904-5	27.4	2
63	Eicosanoid biosynthesis and metabolism in myeloproliferative disorders. <i>Annals of the New York Academy of Sciences</i> , 1994 , 744, 229-36	6.5	2
62	Thromboxane biosynthesis and pharmacologic modulation in progressive glomerulosclerosis. <i>American Journal of Nephrology</i> , 1989 , 9 Suppl 1, 13-6	4.6	2
61	Non-steroidal anti-inflammatory drugs 2011 , 485-493		2
60	Low-Dose Edoxaban for Stroke Prevention in Elderly Patients with Atrial Fibrillation: Comment on the Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE-AF) Trial. <i>European Heart Journal</i> , 2020 , 41, 3882-3883	9.5	2
59	Aspirin Monotherapy vs. DAPT after TAVI: Is Less More? Comment on the POPular TAVI Trial. <i>European Heart Journal</i> , 2020 , 41, 4301-4302	9.5	2
58	The value of sotagliflozin in patients with diabetes and heart failure detracted by an unexpected ending. <i>European Heart Journal</i> , 2021 , 42, 1458-1459	9.5	2
57	Aspirin at 120: Retiring, recombining, or repurposing?. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021 , 5, e12516	5.1	2
56	A SPRINT towards tighter control of blood pressure in hypertension. <i>European Heart Journal</i> , 2021 , 42, 3042-3043	9.5	2
55	1068 Direct Evidence for Long-Lasting Acetylation of Cyclooxygenase-1 Associated With Reduction of Colorectal Mucosa Prostaglandin E2 Levels and Ribosomal Protein S6 Phosphorylation by Low-Dose Aspirin in Subjects Undergoing Colorectal Cancer Screening. <i>Gastroenterology</i> , 2016 , 150, S211	13.3	2
54	Re-purposed antiviral drugs without a purpose in COVID-19: a valuable lesson for clinicians. <i>European Heart Journal</i> , 2021 , 42, 882-883	9.5	2
53	When less is more: dual antiplatelet therapy in elective percutaneous coronary intervention. <i>European Heart Journal</i> , 2021 , 42, 965-966	9.5	2
52	Give genotype-guided dual antiplatelet therapy a second CHANCE.. <i>European Heart Journal</i> , 2022 ,	9.5	1
51	Add-Aspirin trial: A phase III, double blind, placebo-controlled, randomized trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common nonmetastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS1617-TPS1617	2.2	1
50	Age-independent benefits of blood pressure lowering: are they applicable to all patients?. <i>European Heart Journal</i> , 2022 , 43, 448-449	9.5	1
49	Aldosterone receptor antagonism in patients with diabetes and chronic kidney disease: new promises and old problems. <i>European Heart Journal</i> , 2021 , 42, 14-15	9.5	1

48	Background, fundamental concepts, and scientific evidence of the high-sensitivity cardiac troponin 0h/1h-algorithm for early rule-out or rule-in of acute myocardial infarction. <i>European Heart Journal</i> , 2016 , 37, 3318-3323	9.5	1
47	The second life of the ambiguous angiotensin-converting enzyme 2 as a predictive biomarker for cardiometabolic diseases and death. <i>European Heart Journal</i> , 2020 , 41, 4302-4303	9.5	1
46	Management of chronic kidney disease and its cardiovascular complications: has the dawn of a new era arrived? Comment on 'Dapagliflozin in Patients with Chronic Kidney Disease'. <i>European Heart Journal</i> , 2020 , 41, 4231-4232	9.5	1
45	New hope for targeted treatment of obstructive hypertrophic cardiomyopathy: comment on the EXPLORER-HCM trial. <i>European Heart Journal</i> , 2020 , 41, 4089-4090	9.5	1
44	Weak hypothesis? Wrong pharmacologic tool? Inadequate experimental design? Comment on the ATPCI trial. <i>European Heart Journal</i> , 2020 , 41, 4166-4167	9.5	1
43	A one-size-fits-all polypill strategy for primary prevention in the era of precision medicine?. <i>European Heart Journal</i> , 2021 , 42, 561-562	9.5	1
42	A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19. <i>European Heart Journal</i> , 2021 , 42, 1061-1062	9.5	1
41	Abelacimab and factor XI inhibition: a novel mechanism for the prevention of venous thromboembolism. <i>European Heart Journal</i> , 2021 , 42, 4109-4110	9.5	1
40	Documento de Consenso de Expertos sobre el uso de agentes antiplaquetarios. <i>Revista Espanola De Cardiologia</i> , 2004 , 57, 963-980	1.5	0
39	Quadruple combination of quarter doses of blood pressure-lowering agents: a string QUARTET in the symphony of hypertension management?. <i>European Heart Journal</i> , 2021 , 42, 4885-4886	9.5	0
38	StatinWISE sheds new light on statin-related muscle symptoms. <i>European Heart Journal</i> , 2021 , 42, 1726-1727	9.5	0
37	The increased mortality of STEMI patients without risk factors supports the need for evidence-based pharmacotherapy irrespective of perceived low risk. <i>European Heart Journal</i> , 2021 , 42, 2329-2330	9.5	0
36	Are US cardiologists ADAPTABLE to considering low-dose aspirin for secondary prevention?. <i>European Heart Journal</i> , 2021 , 42, 2525-2526	9.5	0
35	Challenging the Role of Aspirin for Long-Term Antiplatelet Therapy?. <i>European Heart Journal</i> , 2021 , 42, 2883-2884	9.5	0
34	Physical activity and mortality reduction: is volume or intensity the key variable?. <i>European Heart Journal</i> , 2021 , 42, 730-731	9.5	0
33	PCSK9 inhibition: Not just LDL-Cholesterol knock down: A glimmer for cancer. <i>European Heart Journal</i> , 2021 , 42, 1130-1131	9.5	0
32	Aspirin-free antiplatelet strategies: is the evidence supporting a paradigm shift?. <i>European Heart Journal</i> , 2021 , 42, 4011-4012	9.5	0
31	The cardiovascular benefits of statins outweigh adverse effects in primary prevention: results of a large systematic review and meta-analysis. <i>European Heart Journal</i> , 2021 , 42, 4518-4519	9.5	0

30	Is tirzepatide in the surpass lane over GLP-1 receptor agonists for the treatment of diabetes?. <i>European Heart Journal</i> , 2021 , 42, 4211-4212	9.5	o
29	Prostanoids, Aspirin, and Related Compounds 2012 , 168-171		
28	Authors' response to Drug Insight: aspirin resistance—fact or fashion? <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007 , 4, E2-E2		
27	Role of platelet activation in dementia. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1998 , 28, 202-8		
26	Renal prostaglandins: biochemistry and functional significance in man. <i>Contributions To Nephrology</i> , 1989 , 69, 55-66	1.6	
25	Occurrence of Leukotrienes in Rat Brain 1985 , 17-26		
24	Prostanoid Generation in Platelet Function 2005 , 267-281		
23	Therapeutic-dose heparin should integrate the standard of care of moderately ill patients with COVID-19 admitted to hospital.. <i>European Heart Journal</i> , 2022 , 43, 365-366	9.5	
22	A fixed-dose combination treatment strategy to reduce premature cardiovascular disease deaths globally.. <i>European Heart Journal</i> , 2021 , 43, 16-17	9.5	
21	Another STEP towards tighter control of blood pressure in the elderly. <i>European Heart Journal</i> , 2021 , 42, 4715-4716	9.5	
20	Innovation in COX-2 Technology. <i>Japanese Journal of Clinical Immunology</i> , 2000 , 23, 683-685		
19	Platelet activation in unstable angina 1989 , 70-77		
18	Renal and Platelet Eicosanoids in Chronic Glomerular Disease 1989 , 121-136		
17	Plättchenaktivierung bei instabiler Angina pectoris 1989 , 76-84		
16	Entry rate and metabolic handling of LTC ₄ in the human circulation 1999 , 139-146		
15	The Effects of Low-Dose Aspirin and Selective Inhibitors of Thromboxane-Synthase on Eicosanoid Production in Man 1985 , 131-140		
14	EMPEROR-Reduced supports the use of SGLT2 inhibitors for the treatment of patients with heart failure and reduced ejection fraction: Comment on the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2020 , 41, 3881-3882	9.5	
13	Out-of-Hospital Cardiac Arrest: Handle With Care-Comment on the Resuscitation Outcomes Consortium Cardiac Epidemiologic Registry. <i>European Heart Journal</i> , 2020 , 41, 4165-4166	9.5	

12	Decline in blood pressure control trends in the US: a real step back: Comment on National Health and Nutrition Examination Survey (NHANES) data. <i>European Heart Journal</i> , 2020 , 41, 3986-3987	9.5
11	Interleukin-1 blockade: a paradigm shift in the treatment of patients with recurrent pericarditis?. <i>European Heart Journal</i> , 2021 , 42, 1287-1288	9.5
10	Vulnerable non-culprit coronary plaques: are they worth treating?. <i>European Heart Journal</i> , 2021 , 42, 2233-2234	9.5
9	Iron heart. <i>European Heart Journal</i> , 2021 , 42, 809-810	9.5
8	Rivaroxaban, a novel option for patients with atrial fibrillation and a bioprosthetic mitral valve. <i>European Heart Journal</i> , 2021 , 42, 811-812	9.5
7	Preventing a diabetes pandemic through lifestyle intervention. <i>European Heart Journal</i> , 2021 , 42, 226-227.5	9.5
6	Gustav Born and life as "a series of ripples widening out from an original centre". <i>Platelets</i> , 2018 , 29, 761-762	3.6
5	Occluding to prevent occlusion. <i>European Heart Journal</i> , 2021 , 42, 3224-3225	9.5
4	Worsening of risk factor control in US diabetic patients: a call to action. <i>European Heart Journal</i> , 2021 , 42, 3120-3121	9.5
3	A newly designed glucagon-like peptide-1 receptor agonist reduces cardiovascular and renal events in high-risk type 2 diabetes. <i>European Heart Journal</i> , 2021 , 42, 3902-3903	9.5
2	Does abbreviated dual antiplatelet therapy after PCI provide a clinically meaningful trade-off between bleeding and ischaemic events in patients at high risk for bleeding?. <i>European Heart Journal</i> , 2021 , 42, 4418-4419	9.5
1	First in man: gene editing for the treatment of transthyretin amyloidosis. <i>European Heart Journal</i> , 2021 , 42, 3597-3598	9.5